Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 87

Similar articles for PubMed (Select 23104270)

1.

Doxorubicin and 5-fluorouracil resistant hepatic cancer cells demonstrate stem-like properties.

Vu NB, Nguyen TT, Tran LC, Do CD, Nguyen BH, Phan NK, Pham PV.

Cytotechnology. 2013 Aug;65(4):491-503. doi: 10.1007/s10616-012-9511-9. Epub 2012 Oct 27.

2.

Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma.

Tomuleasa C, Soritau O, Rus-Ciuca D, Pop T, Todea D, Mosteanu O, Pintea B, Foris V, Susman S, Kacsó G, Irimie A.

J Gastrointestin Liver Dis. 2010 Mar;19(1):61-7.

3.

Efficient enrichment of hepatic cancer stem-like cells from a primary rat HCC model via a density gradient centrifugation-centered method.

Liu WH, Wang X, You N, Tao KS, Wang T, Tang LJ, Dou KF.

PLoS One. 2012;7(4):e35720. doi: 10.1371/journal.pone.0035720. Epub 2012 Apr 25.

4.

Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma.

Tomuleasa C, Soritau O, Fischer-Fodor E, Pop T, Susman S, Mosteanu O, Petrushev B, Aldea M, Acalovschi M, Irimie A, Kacso G.

Hematol Oncol Stem Cell Ther. 2011;4(2):60-6.

5.

EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma.

Terris B, Cavard C, Perret C.

J Hepatol. 2010 Feb;52(2):280-1. doi: 10.1016/j.jhep.2009.10.026. Epub 2009 Nov 10.

6.

A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.

Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N, Henderson DR.

Cancer Res. 2001 Sep 1;61(17):6428-36.

7.

Evidence of CD90+CXCR4+ cells as circulating tumor stem cells in hepatocellular carcinoma.

Zhu L, Zhang W, Wang J, Liu R.

Tumour Biol. 2015 Jul;36(7):5353-60. doi: 10.1007/s13277-015-3196-6. Epub 2015 Feb 12.

PMID:
25672610
8.

Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines.

Cao L, Zhou Y, Zhai B, Liao J, Xu W, Zhang R, Li J, Zhang Y, Chen L, Qian H, Wu M, Yin Z.

BMC Gastroenterol. 2011 Jun 14;11:71. doi: 10.1186/1471-230X-11-71.

9.

Maintenance of retinal cancer stem cell-like properties through long-term serum-free culture from human retinoblastoma.

Ma B, Lei X, Guan Y, Mou LS, Yuan YF, Yue H, Lu Y, Xu GT, Qian J.

Oncol Rep. 2011 Jul;26(1):135-43. doi: 10.3892/or.2011.1291. Epub 2011 Apr 29.

PMID:
21573498
10.

Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo.

Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, Fazioli F, Pirozzi G, Papaccio G.

FASEB J. 2011 Jun;25(6):2022-30. doi: 10.1096/fj.10-179036. Epub 2011 Mar 8.

11.

CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.

Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY.

Oncogene. 2008 Mar 13;27(12):1749-58. Epub 2007 Sep 24.

PMID:
17891174
12.

CD49f(high) cells retain sphere-forming and tumor-initiating activities in human gastric tumors.

Fukamachi H, Seol HS, Shimada S, Funasaka C, Baba K, Kim JH, Park YS, Kim MJ, Kato K, Inokuchi M, Kawachi H, Yook JH, Eishi Y, Kojima K, Kim WH, Jang SJ, Yuasa Y.

PLoS One. 2013 Aug 28;8(8):e72438. doi: 10.1371/journal.pone.0072438. eCollection 2013.

13.

Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors.

Rutella S, Bonanno G, Procoli A, Mariotti A, Corallo M, Prisco MG, Eramo A, Napoletano C, Gallo D, Perillo A, Nuti M, Pierelli L, Testa U, Scambia G, Ferrandina G.

Clin Cancer Res. 2009 Jul 1;15(13):4299-311. doi: 10.1158/1078-0432.CCR-08-1883. Epub 2009 Jun 9.

14.

Integrated analysis of miRNA, gene, and pathway regulatory networks in hepatic cancer stem cells.

Ding M, Li J, Yu Y, Liu H, Yan Z, Wang J, Qian Q.

J Transl Med. 2015 Aug 11;13:259. doi: 10.1186/s12967-015-0609-7.

15.

Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme.

Broadley KW, Hunn MK, Farrand KJ, Price KM, Grasso C, Miller RJ, Hermans IF, McConnell MJ.

Stem Cells. 2011 Mar;29(3):452-61. doi: 10.1002/stem.582.

16.

Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts.

Martin-Padura I, Marighetti P, Agliano A, Colombo F, Larzabal L, Redrado M, Bleau AM, Prior C, Bertolini F, Calvo A.

Lab Invest. 2012 Jul;92(7):952-66. doi: 10.1038/labinvest.2012.65. Epub 2012 Apr 30.

17.

[A new method for purification and identification of hepatocellular carcinoma stem cell of SMMC-7721].

Wang Y, Liu YH, Jiang JS, Cui HB.

Zhonghua Yi Xue Za Zhi. 2012 Dec 25;92(48):3434-7. Chinese.

PMID:
23327707
18.

The power and the promise of liver cancer stem cell markers.

Liu LL, Fu D, Ma Y, Shen XZ.

Stem Cells Dev. 2011 Dec;20(12):2023-30. doi: 10.1089/scd.2011.0012. Epub 2011 Aug 4. Review.

PMID:
21651381
19.

Differences in the properties and mirna expression profiles between side populations from hepatic cancer cells and normal liver cells.

Liu WH, Tao KS, You N, Liu ZC, Zhang HT, Dou KF.

PLoS One. 2011;6(8):e23311. doi: 10.1371/journal.pone.0023311. Epub 2011 Aug 3.

20.

CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells.

Lan X, Wu YZ, Wang Y, Wu FR, Zang CB, Tang C, Cao S, Li SL.

Int J Mol Med. 2013 Feb;31(2):315-24. doi: 10.3892/ijmm.2012.1208. Epub 2012 Dec 6.

PMID:
23233126
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk